E-viri
Recenzirano
-
Esteban-Fernández, Alberto; Gómez-Otero, Inés; López-Fernández, Silvia; Santamarta, Miguel Rodríguez; Pastor-Pérez, Francisco J; Fluvià-Brugués, Paula; Pérez-Rivera, José-Ángel; López López, Andrea; García-Pinilla, José Manuel; Palomas, Juan Luis Bonilla; Bonet, Luis Almenar; Cobo-Marcos, Marta; Mateo, Virgilio Martínez; Llergo, Javier Torres; Fernández, Vanesa Alonso; Vives, Cristina Goena; de Juan Bagudá, Javier; Benedicto, Alba Maestro; de Polavieja, José Ignacio Morgado; Solla-Ruiz, Itziar; Solé-González, Eduard; Cardona, Montserrat; Olaetxea, Javier Rekondo; Cortés, Carolina Ortiz; Dosantos, Victor Martínez; López, Antonio Gámez; Amao, Elvis; Sánchez, Borja Casas; Torres, Edgardo Alania; Carrillo, Víctor Gómez; García-Fuertes, Daniel; Ridocci-Soriano, Francisco
Clinical research in cardiology, 06/2023Journal Article
Heart failure (HF) guidelines recommend treating all patients with HF and reduced ejection fraction (HFrEF) with quadruple therapy, although they do not establish how to start it. This study aimed to evaluate the implementation of these recommendations, analyzing the efficacy and safety of the different therapeutic schedules. Prospective, observational, and multicenter registry that evaluated the treatment initiated in patients with newly diagnosed HFrEF and its evolution at 3 months. Clinical and analytical data were collected, as well as adverse reactions and events during follow-up. Five hundred and thirty-three patients were included, selecting four hundred and ninety-seven, aged 65.5 ± 12.9 years (72% male). The most frequent etiologies were ischemic (25.5%) and idiopathic (21.1%), with a left ventricular ejection fraction of 28.7 ± 7.4%. Quadruple therapy was started in 314 (63.2%) patients, triple in 120 (24.1%), and double in 63 (12.7%). Follow-up was 112 days IQI 91; 154, with 10 (2%) patients dying. At 3 months, 78.5% had quadruple therapy (p < 0.001). There were no differences in achieving maximum doses or reducing or withdrawing drugs (< 6%) depending on the starting scheme. Twenty-seven (5.7%) patients had any emergency room visits or admission for HF, less frequent in those with quadruple therapy (p = 0.02). It is possible to achieve quadruple therapy in patients with newly diagnosed HFrEF early. This strategy makes it possible to reduce admissions and visits to the emergency room for HF without associating a more significant reduction or withdrawal of drugs or significant difficulty in achieving the target doses.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.